Paper39272178
In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma.
Krug A and 7 others. J Exp Clin Cancer Res, 2024. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma. Papers, record 39272178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39272178
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Chimeric Antigen | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Lymphoma, T-Cell | Major topic |
| Disease Models, Animal | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Immunoblastic Lymphadenopathy | |
| CD8-Positive T-Lymphocytes | |
| Cell Line, Tumor |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ANR-16-CE16-0024-01 | Agence Nationale de la Recherche | PubMed | ||
| GET-IN | H2020 Marie Skłodowska-Curie Actions | PubMed | ||
| PhD followship | Ministère de l'Enseignement Supérieur et de la Recherche | PubMed |
Source PubMed
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29398449 | RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. | Cancer Cell | 2018 | https://conductscience.org/library/papers/29398449 | PubMed |
| 2 | 27281338 | Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment. | PLoS Pathog | 2016 | https://conductscience.org/library/papers/27281338 | PubMed |
| 3 | 29769264 | RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. | Blood | 2018 | https://conductscience.org/library/papers/29769264 | PubMed |
| 4 | 32485137 | In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes. | Mol Ther | 2020 | https://conductscience.org/library/papers/32485137 | PubMed |
| 5 | 31118293 | Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. | Sci Transl Med | 2019 | https://conductscience.org/library/papers/31118293 | PubMed |
| 6 | 25794369 | Cutaneous manifestations of angioimmunoblastic T-cell lymphoma: clinical and pathological characteristics. | Am J Dermatopathol | 2015 | https://conductscience.org/library/papers/25794369 | PubMed |
| 7 | 28115369 | Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. | Blood | 2017 | https://conductscience.org/library/papers/28115369 | PubMed |
| 8 | 17873758 | Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. | Medicine (Baltimore) | 2007 | https://conductscience.org/library/papers/17873758 | PubMed |
| 9 | 20453843 | PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. | Nat Immunol | 2010 | https://conductscience.org/library/papers/20453843 | PubMed |
| 10 | 32796826 | New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. | Oncogenesis | 2020 | https://conductscience.org/library/papers/32796826 | PubMed |
| 11 | 30224381 | In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. | EMBO Mol Med | 2018 | https://conductscience.org/library/papers/30224381 | PubMed |
| 12 | 30275568 | Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. | Nat Med | 2018 | https://conductscience.org/library/papers/30275568 | PubMed |
| 13 | 26232436 | Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors. | J Immunol | 2015 | https://conductscience.org/library/papers/26232436 | PubMed |
| 14 | 34729380 | Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8. | Mol Ther Methods Clin Dev | 2021 | https://conductscience.org/library/papers/34729380 | PubMed |
| 15 | 36736318 | IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. | Cancer Cell | 2023 | https://conductscience.org/library/papers/36736318 | PubMed |
| 16 | 33846629 | Genetic in vivo engineering of human T lymphocytes in mouse models. | Nat Protoc | 2021 | https://conductscience.org/library/papers/33846629 | PubMed |
| 17 | 25692700 | ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. | Immunity | 2015 | https://conductscience.org/library/papers/25692700 | PubMed |
| 18 | 37866783 | Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies. | Transplant Cell Ther | 2024 | https://conductscience.org/library/papers/37866783 | PubMed |
| 19 | 27269947 | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27269947 | PubMed |
| 20 | 19236377 | Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. | Br J Haematol | 2009 | https://conductscience.org/library/papers/19236377 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942823 | Unraveling Vulnerabilities and Pathways Responsible for AITL Malignancy to Improve Patients' Treatment. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42942823 | PubMed |
| 42802858 | Advancing In Vivo Chimeric Antigen Receptor T-Cell Engineering to Accelerate Clinical Translation. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42802858 | PubMed |
| 42502508 | Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector for in vivo CD19-directed CAR-T therapy. | Mol Ther Adv | 2026 | https://conductscience.org/library/papers/42502508 | PubMed |
| 42170676 | Engineering precision oncology: Targeting tumors and immune cells with lentiviral vectors. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42170676 | PubMed |
| 42065060 | In Vivo CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation. | Oncol Res | 2026 | https://conductscience.org/library/papers/42065060 | PubMed |
| 41575553 | Radiotherapy in addition to systemic therapy reduces the early mortality of angioimmunoblastic T-cell lymphoma. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41575553 | PubMed |
| 41535417 | Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41535417 | PubMed |
| 41261423 | In vivo CAR cell therapy: from bench to bedside. | J Hematol Oncol | 2025 | https://conductscience.org/library/papers/41261423 | PubMed |
| 41079670 | Revolution in Cell Therapy: In Vivo Chimeric-Antigen-Receptor-T-Cell Therapy Breakthroughs and Promises for the Future. | Research (Wash D C) | 2025 | https://conductscience.org/library/papers/41079670 | PubMed |
| 41028170 | In vivo chimeric antigen receptor (CAR)-T cell therapy. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/41028170 | PubMed |
| 41016988 | Cancer gene therapy: historical perspectives, current applications, and future directions. | Funct Integr Genomics | 2025 | https://conductscience.org/library/papers/41016988 | PubMed |
| 40560424 | Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advances. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40560424 | PubMed |
| 40346022 | Scavenging Reactive Oxygen Species by Cerium Oxide Nanoparticles Prevents Death in a Peripheral T Cell Lymphoma Preclinical Mouse Model. | ACS Nano | 2025 | https://conductscience.org/library/papers/40346022 | PubMed |
| 40231980 | Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma. | Cancer Biol Med | 2025 | https://conductscience.org/library/papers/40231980 | PubMed |
| 40027134 | Global research prospects and trends in TFH cells and tumors: a bibliometric analysis. | Front Oncol | 2025 | https://conductscience.org/library/papers/40027134 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39272178
GET https://conductscience.org/api/papers/v1/39272178/references?page=2